Myeloproliferative neoplasm natural history, complications, and prognosis
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm natural history, complications, and prognosis |
|
FDA on Myeloproliferative neoplasm natural history, complications, and prognosis |
|
on Myeloproliferative neoplasm natural history, complications, and prognosis |
|
Myeloproliferative neoplasm natural history, complications, and prognosis in the news |
|
Blogs on Myeloproliferative neoplasm natural history, complications, and prognosis |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
If left untreated, patients with myeloproliferative neoplasm may progress to develop weight loss, fever, and night sweats. Common complications of myeloproliferative neoplasm include splenomegaly, bleeding, and thrombosis. Prognosis is generally good with treatment, and the 3-year survival rate of patients with myeloproliferative neoplasm is approximately 35%.[1][2]
Natural History
The symptoms of myeloproliferative neoplasm usually develop in the sixth decade of life and start with symptoms such as anorexia, weight loss, and fatigue. The onset of symptoms is usually insidious, and the symptoms do not frequently cause many problems initially. The disease progresses quite slowly, typically over a period of months to years. However, without treatment, patients will develop severe symptoms, such as abdominal pain, bruising, bleeding, thrombosis, fever, and infection which may eventually lead to death.[1][2] The natural history of myeloproliferative neoplasm is dependent upon the subtype of myeloproliferative neoplasm and by the prognostic group. The natural history of myelodysplastic syndrome / myeloproliferative neoplasm unclassifiable (MDS/MPN, U) is poor.[3] In general, the natural history of patients above the age of 60, the presence of a JAK2 mutation, and a history of thrombosis is worse than the natural history of patients under age 60, the absence of JAK2 mutation, and no history of thrombosis.[4] Thrombosis is an inevitable part of the natural history of many subtypes of myeloproliferative neoplasms, especially polycythemia vera and essential thrombocythemia. Approximately 41% of patients with polycythemia vera, for example, will experience thrombosis.[5]
Complications
Myeloproliferative neoplasm may lead to the following complications:[6][2][7]
- Spleen
- Fatigue
- Anemia
- Weight loss
- Leukocytosis
Prognosis
The prognosis of Myeloproliferative neoplasm is good with treatment. Without treatment, Myeloproliferative neoplasm may result in death. The 5- and 10-year survival rates for myeloproliferative neoplasm are 74% to 93% and 61% to 84%, respectively.
References
- ↑ 1.0 1.1 Ma X, Does M, Raza A, Mayne ST (2007). "Myelodysplastic syndromes: incidence and survival in the United States". Cancer. 109 (8): 1536–42. doi:10.1002/cncr.22570. PMID 17345612.
- ↑ 2.0 2.1 2.2 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.
- ↑ DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC; et al. (2014). "Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy". Leukemia. 28 (4): 958–61. doi:10.1038/leu.2014.8. PMC 3981947. PMID 24492324.
- ↑ Vannucchi AM (2017). "From leeches to personalized medicine: evolving concepts in the management of polycythemia vera". Haematologica. 102 (1): 18–29. doi:10.3324/haematol.2015.129155. PMC 5210229. PMID 27884974.
- ↑ Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK; et al. (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F". J Clin Oncol. 33 (33): 3953–60. doi:10.1200/JCO.2015.61.6474. PMC 4979103. PMID 26324368.
- ↑ Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC; et al. (2012). "Philadelphia-negative chronic myeloproliferative neoplasms". Rev Bras Hematol Hemoter. 34 (2): 140–9. doi:10.5581/1516-8484.20120034. PMC 3459391. PMID 23049404.
- ↑ Frewin, R (October 2012). "Headache in essential thrombocythaemia" (PDF). International Journal of Clinical Practice. 66 (10): 976–83. doi:10.1111/j.1742-1241.2012.02986.x. PMC 3469735. PMID 22889110. Unknown parameter
|coauthors=ignored (help)